pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 8085-8093

  Tonini, Tiziana ^a,b   Gabellini, Chiara ^a,c   Bagella, Luigi ^a,b   D'Andrilli, Giuseppina ^a,d   Masciullo, Valeria ^a   Romano, Gaetano ^e   Scambia, Giovanni ^d   Zupi, Gabriella ^c   Giordano, Antonio ^a,b  

^a Temple University   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CAMPTOTHECIN; DOXORUBICIN; PACLITAXEL; PROTEIN P130; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CAOV 3; CHEMOSENSITIVITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; COLONY-FORMING UNITS ASSAY; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROTEINS; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P130; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9744230672     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0996     Document Type: Article

References (50)

1. Altaha R, Reed E, Abraham J. Breast and ovarian cancer genetics and prevention. WV Med J 2003;99:187-91.
2. Wang C, Horiuchi A, Imai T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004;202:215-23.
3. Mayol X, Grana X, Baldi A, et al. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993;8:2561-6.
4. Masciullo V, Khalili K, Giordano A. The Rb family of cell cycle regulatory factors: clinical implications. Int J Oncol 2000;17:897-902.
5. Claudio PP, Howard CM, Baldi A, et al. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994;54:5556-60.
6. D'Andrilli G, Masciullo V, Bagella L, et al. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin Cancer Res 2004;10:3098-103.
7. Caputi M, Groeger AM, Esposito V, et al. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer. Clin Cancer Res 2002;8:3850-6.
8. k1p1, p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002;8:1808-15.
9. Fan G, Ma X, Kren BT, Steer CJ. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene 1996;12:1909-19.
10. Berry DE, Lu Y, Schmidt B, et al. Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene 1996;12:1809-19.
11. Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia 2000;2:291-9.
12. Lauricella M, Calvaruso G, Carabillo M, et al. pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase. FEBS Lett 2001;499:191-7.
13. Lee MH, Williams BO, Mulligan G, et al. Targeted disruptionof p107: functional overlap between p107 and Rb. Genes Dev 1996;10:1621-32.
14. Pucci B, Claudio PP, Masciullo V, et al. pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation. Oncogene 2002;21:5897-905.
15. Haas-Kogan DA, Kogan SC, Levi D, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995;14:461-72.
16. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
17. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
18. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
19. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994;54:4355-61.
20. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-42.
21. Giles FJ, Cortes JE, Thomas DA, et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 2002;8:2134-41.
22. Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer. Gynecol Oncol 2003;90:S45-50.
23. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
24. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature (Lond) 1994;369:156-60.
25. 2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 1997;272:4631-6.
26. 2-terminal kinase activation mediated by UV-induced DNA lesions in melanoma and fibroblast cells. Cell Growth Differ 1995;6:1437-46.
27. Claudio PP, Fratta L, Farina F, et al. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. Circ Res 1999;85:1032-9.
28. Biroccio A, Benassi B, Amodei S, et al. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 2001;60:174-82.
29. Baldi A, Esposito V, De Luca A, et al. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res 1996;2:1239-45.
30. Hu QJ, Bautista C, Edwards GM, et al. Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides. Mol Cell Biol 1991;11:5792-9.
31. De Luca A, MacLachlan TK, Bagella L, et al. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J Biol Chem 1997;272:20971-4.
32. Chaudhuri S, Seal A, Gupta MD. Autophosphorylation-dependent activation of a calcium-dependent protein kinase from groundnut. Plant Physiol 1999;120:859-66.
33. Andoh T. Signal transduction pathways leading to cell cycle arrest and apoptosis induced by DNA topoisomerase poisons. Cell Biochem Biophys 2000;33:181-8.
34. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997;75:337-49.
35. Courtois S, de Fromentel CC, Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 2004;23:631-8.
36. WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003;6:183-95.
37. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52.
38. Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997;89:2986-93.
39. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
40. Tron VA, Trotter MJ, Tang L, et al. p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol 1998;153:579-85.
41. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29:323-33, 2000.
42. Clerk A, Sugden PH. Cell stress-induced phosphorylation of ATF2 and c-Jun transcription factors in rat ventricular myocytes. Biochem J 1997;325:801-10.
43. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003;2:199-201.
44. 2-terminal kinase are expressed in primary glial tumors. Cancer Res 2003;63:250-5.
45. Susini T, Baldi F, Howard CM, et al. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J Clin Oncol 1998;16:1085-93.
46. Massaro-Giordano M, Baldi G, De Luca A, Baldi A, Giordano A. Differential expression of the retinoblastoma gene family members in choroidal melanoma: prognostic significance. Clin Cancer Res 1999;5:1455-8.
47. Dou QP. Putative roles of retinoblastoma protein in apoptosis. Apoptosis 1997;2:5-18.
48. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-48.
49. Minden A, Lin A, Smeal T, et al. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 1994;14:6683-8.
50. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004;23:596-604.